Third-quarter net product revenue was $45.5 million, down 70% year-over-year. Full-year 2026 total net revenue is now expected at $179 million to $200 million, a decline of 65% to 68%. The FDA will extend the MNUVIX PDUFA target date from April 24, 2027, after identifying 18 items requiring remediation at the Norwood facility.
ORGO · Organogenesis Holdings Inc.
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Price & Indicators
Key stats
- Short volume, last session
- 69%
- Last earnings
- Nov 5, 2026
- Latest filing
- 10-Q · Nov 5
- Price history
- Jan 2020 to Nov 2026
Up next
Latest documents
Organogenesis reported a $179.1 million net loss for the nine months ended September 30, 2026, while net product revenue fell (63%) amid clinician confusion and market disruption following CMS’s December 2025 comments on discarded product.
Organogenesis Holdings Inc. reported revenue of $45.5 million, down 70%, and a net loss of $29.6 million. Cash was $26.9 million with no debt at September 30, 2026; 2026 revenue guidance is $179.4 million to $200.0 million.
Metrics snapshot
Useful current figures from the complete screener profile.
Quarterly results
* Q4 derived as the full year minus Q1 to Q3.
AI Brief
Q3 FY26 earnings call · Nov 5, 2026TL;DR. Q3 revenue increased 6% sequentially, claims analysis indicates market-share gains, operating expenses fell 42%, management expects positive adjusted EBITDA in the fourth quarter, and the FDA accepted the Mnuvix BLA for review. However, net product revenue and gross margin fell sharply year over year, operating, net and adjusted EBITDA results deteriorated, cash declined to $26.9 million, guidance reflects a more measured recovery, low-cost inventory is delaying recovery, and Mnuvix faces remediation requirements, a delayed timeline and added cost.
- + Q3 revenue increased 6% sequentially as growth trends improved. new
- + Claims analysis indicates market share increased more than 30% versus Q1. new
- + The PREPARE trial achieved its primary endpoints and showed statistically significant wound-closure improvements at 12 weeks. new
- + Q3 operating expenses declined 42% year over year. new
- + Management expects positive adjusted EBITDA generation in the fourth quarter. new
- + The FDA accepted the Mnuvix BLA for review. new
- − Q3 net product revenue declined 70% year over year and gross margin fell to 52% from 76%. new
- − Updated full-year guidance reflects a more measured revenue recovery. new
- − Excess low-cost inventory from exiting competitors is delaying the skin-substitute market recovery. new
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Still-open targets the latest release did not restate under the same label.
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders SellIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Adjusted EBITDA non-GAAP | -104.91M | Nine Months Ended September 30, 2026 | — |
|
|
|||
| Adjusted EBITDA loss non-GAAP | $104.9M | the nine months ended September 30, 2026 | — |
|
|
|||
| Adjusted net income (loss) non-GAAP | -162.07M | Nine Months Ended September 30, 2026 | — |
| Adjusted net loss non-GAAP | $162.1M | the nine months ended September 30, 2026 | — |
|
|
|||
| EBITDA non-GAAP | -131.09M | Nine Months Ended September 30, 2026 | — |
|
|
|||
| Non-GAAP operating income (loss) non-GAAP | -126.11M | Nine Months Ended September 30, 2026 | — |
| Non-GAAP operating loss non-GAAP | $126.1M | the nine months ended September 30, 2026 | — |
|
|
|||
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Drug Manufacturers - Specialty & Generic — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
ORGO
this stock
Organogenesis Holdings Inc.
|
$102.44M | -84.8% | +17.0% | — | 12.0% |
|
TAK
Takeda Pharmaceutical Co Ltd
|
$68.40B | +37.3% | — | — | 0.1% |
|
GALDY
Galderma Group AG
|
$50.89B | +5.3% | — | — | 0.0% |
|
TEVA
Teva Pharmaceutical Industries Ltd
|
$44.97B | +23.5% | +4.3% | 87.6 | 2.4% |
|
JHPCY
Jiangsu Hengrui Pharmaceuticals Co., Ltd.
|
$40.66B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every section- Filed
- Nov 5, 2026
- This year
- 13
Organogenesis Holdings Inc. reported revenue of $45.5 million, down 70%, and a net loss of $29.6 million. Cash was $26.9 million with no debt at September 30, 2026; 2026 revenue guidance is $179.4 million to $200.0 million.
ViewPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| ORGO | -18.2% | -23.4% | -66.6% | +2.8% | -84.8% |
| SPY | -5.5% | -6.3% | -5.6% | -5.3% | +5.0% |
| vs SPY | -12.8% | -17.1% | -60.9% | +8.0% | -89.7% |